‘Drug treatment regimens and personalised medicine consultancy’ Physiomics (PYC) has followed recent half-year results with a “pleased to announce… third contract by existing client, Numab Therapeutics”. So what of a current 2.3p share price?
Biopharma technology company Physiomics (PYC) has announced its year ended 30th June performance “in-line with market expectations” and expected increased revenue this year. So what of a current share price response more than 5% higher to above 3p?
The lower end of the AIM market seems to be littered with small companies that haven’t made any real progress over the years, in terms of shareholder returns, and I’m often left wondering what the point of them being listed is, given the additional costs that involves.
Physiomics (PYC) has updated including “we already see that clinical trials and patient recruitment are showing signs of returning to normality” and “the company's cash position remains strong, and it is estimated that on 30 June 2021 its net asset position will be c.£1.1m, the majority of which is cash”. Why then have the shares currently responded to 5.95p, more than 7% lower?...
Notifications of major holdings in the shares of a company are designed to keep investors informed of when large shareholders increase or decrease their position by a significant amount.
The reality is the odds are stacked against you in the Aim market particularly if your relative experience of the small cap market is one based on theory or conjecture. That brings me to Physiomics (PYC) – shares in which gained 113% yesterday.
Physiomics is another of the more obscure minnows showing up on the technical radar at the moment, and even though the current share price which is in the middle of the past one-year range may not immediately appear to be compelling as a buying opportunity, from a technical perspective there is plenty of excitement to be had.
Time left: 22:33:52